152 related articles for article (PubMed ID: 14582455)
1. Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Hough G; Wagner A; Nakamura K; Garber DW; Datta G; Segrest JP; Hama S; Fogelman AM
Curr Opin Investig Drugs; 2003 Sep; 4(9):1100-4. PubMed ID: 14582455
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.
Sherman CB; Peterson SJ; Frishman WH
Cardiol Rev; 2010; 18(3):141-7. PubMed ID: 20395699
[TBL] [Abstract][Full Text] [Related]
3. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein A-I mimetic peptides.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Yu N; Ansell BJ; Datta G; Garber DW; Fogelman AM
Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1325-31. PubMed ID: 15831812
[TBL] [Abstract][Full Text] [Related]
5. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease.
Ou J; Ou Z; Jones DW; Holzhauer S; Hatoum OA; Ackerman AW; Weihrauch DW; Gutterman DD; Guice K; Oldham KT; Hillery CA; Pritchard KA
Circulation; 2003 May; 107(18):2337-41. PubMed ID: 12732610
[TBL] [Abstract][Full Text] [Related]
6. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia.
Belalcazar LM; Merched A; Carr B; Oka K; Chen KH; Pastore L; Beaudet A; Chan L
Circulation; 2003 Jun; 107(21):2726-32. PubMed ID: 12742997
[TBL] [Abstract][Full Text] [Related]
7. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol.
Navab M; Anantharamaiah GM; Hama S; Garber DW; Chaddha M; Hough G; Lallone R; Fogelman AM
Circulation; 2002 Jan; 105(3):290-2. PubMed ID: 11804981
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor.
Moore RE; Kawashiri MA; Kitajima K; Secreto A; Millar JS; Pratico D; Rader DJ
Arterioscler Thromb Vasc Biol; 2003 Oct; 23(10):1914-20. PubMed ID: 12933536
[TBL] [Abstract][Full Text] [Related]
9. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide.
Van Lenten BJ; Wagner AC; Anantharamaiah GM; Garber DW; Fishbein MC; Adhikary L; Nayak DP; Hama S; Navab M; Fogelman AM
Circulation; 2002 Aug; 106(9):1127-32. PubMed ID: 12196340
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.
Nachtigal P; Pospisilova N; Jamborova G; Pospechova K; Solichova D; Andrys C; Zdansky P; Micuda S; Semecky V
Life Sci; 2008 Mar; 82(13-14):708-17. PubMed ID: 18289605
[TBL] [Abstract][Full Text] [Related]
11. Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia.
Boullier A; Hennuyer N; Tailleux A; Furman C; Duverger N; Caillaud JM; Castro G; Fievet C; Fruchart JC; Duriez P
Clin Sci (Lond); 2001 Mar; 100(3):343-55. PubMed ID: 11222122
[TBL] [Abstract][Full Text] [Related]
12. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein A-I mimetic peptide inhibits atherosclerosis by altering plasma metabolites in hypercholesterolemia.
Ou ZJ; Li L; Liao XL; Wang YM; Hu XX; Zhang QL; Wang ZP; Yu H; Zhang X; Hu P; Xu YQ; Liang QL; Ou JS; Luo G
Am J Physiol Endocrinol Metab; 2012 Sep; 303(6):E683-94. PubMed ID: 22535745
[TBL] [Abstract][Full Text] [Related]
14. Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.
Kitayama K; Nishizawa T; Abe K; Wakabayashi K; Oda T; Inaba T; Amemiya Y
J Pharm Pharmacol; 2006 Dec; 58(12):1629-38. PubMed ID: 17331327
[TBL] [Abstract][Full Text] [Related]
15. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes.
Van Lenten BJ; Wagner AC; Navab M; Anantharamaiah GM; Hui EK; Nayak DP; Fogelman AM
Circulation; 2004 Nov; 110(20):3252-8. PubMed ID: 15533864
[TBL] [Abstract][Full Text] [Related]
16. Effect of macrophage-derived apolipoprotein E on hyperlipidemia and atherosclerosis of LDLR-deficient mice.
Shi W; Wang X; Wong J; Hedrick CC; Wong H; Castellani LW; Lusis AJ
Biochem Biophys Res Commun; 2004 Apr; 317(1):223-9. PubMed ID: 15047172
[TBL] [Abstract][Full Text] [Related]
17. Reverse D4F, an apolipoprotein-AI mimetic peptide, inhibits atherosclerosis in ApoE-null mice.
Qin S; Kamanna VS; Lai JH; Liu T; Ganji SH; Zhang L; Bachovchin WW; Kashyap ML
J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):334-43. PubMed ID: 22308547
[TBL] [Abstract][Full Text] [Related]
18. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation.
Choudhury RP; Rong JX; Trogan E; Elmalem VI; Dansky HM; Breslow JL; Witztum JL; Fallon JT; Fisher EA
Arterioscler Thromb Vasc Biol; 2004 Oct; 24(10):1904-9. PubMed ID: 15319266
[TBL] [Abstract][Full Text] [Related]
19. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet.
Ou J; Wang J; Xu H; Ou Z; Sorci-Thomas MG; Jones DW; Signorino P; Densmore JC; Kaul S; Oldham KT; Pritchard KA
Circ Res; 2005 Nov; 97(11):1190-7. PubMed ID: 16224061
[TBL] [Abstract][Full Text] [Related]
20. Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice.
Navab M; Hama S; Hough G; Fogelman AM
Circulation; 2003 Oct; 108(14):1735-9. PubMed ID: 14504179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
